These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 28013483)

  • 81. Optimal conditioning regimen for haplo-identical stem cell transplantation in adult patients with acquired severe aplastic anemia: Prospective de-escalation study of TBI and ATG dose.
    Lee SE; Park SS; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Lee JW
    Am J Hematol; 2018 Nov; 93(11):1368-1375. PubMed ID: 30117176
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Haploidentical stem cell transplantation with purified CD34 cells after a chemotherapy-alone conditioning regimen.
    Lacerda JF; Martins C; Carmo JA; Lourenço F; Juncal C; Rodrigues A; Vilalobos I; Moura MC; Ligeiro D; Martinho A; Lacerda JM
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):633-42. PubMed ID: 14569559
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Fludarabine and melphalan conditioning with tacrolimus as GVHD prophylaxis for allogeneic stem cell transplant recipients is an effective reduced-intensity combination regimen compared to the conventional regimen.
    Imataki O; Ohnishi H; Ohbayashi Y; Kitanaka A; Kubota Y; Ishida T; Tanaka T
    Int J Clin Oncol; 2009 Jun; 14(3):197-201. PubMed ID: 19593609
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Haploidentical stem cell transplantation for acute leukemia.
    Aversa F; Terenzi A; Felicini R; Carotti A; Falcinelli F; Tabilio A; Velardi A; Martelli MF
    Int J Hematol; 2002 Aug; 76 Suppl 1():165-8. PubMed ID: 12430847
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Reduced-intensity conditioning regimen with low-dose ATG-F for unrelated bone marrow transplant is associated with lower non-relapse mortality than a regimen with low-dose TBI: a single-center retrospective analysis of 103 cases.
    Fuji S; Ueno N; Hiramoto N; Asakura Y; Yakushijin K; Kamiyama Y; Kurosawa S; Kim SW; Heike Y; Yamashita T; Fukuda T
    Int J Hematol; 2013 Nov; 98(5):608-14. PubMed ID: 24092050
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.
    Ciurea SO; Saliba R; Rondon G; Pesoa S; Cano P; Fernandez-Vina M; Qureshi S; Worth LL; McMannis J; Kebriaei P; Jones RB; Korbling M; Qazilbash M; Shpall EJ; Giralt S; de Lima M; Champlin RE; Gajewski J
    Bone Marrow Transplant; 2010 Mar; 45(3):429-36. PubMed ID: 19668237
    [TBL] [Abstract][Full Text] [Related]  

  • 87. HLA-haploidentical peripheral blood stem cell transplantation following reduced-intensity conditioning with very low-dose antithymocyte globulin for relapsed/refractory acute leukemia in pediatric patients: a single-institution retrospective analysis.
    Higuchi K; Sawada A; Kondo O; Okada Y; Tsujimoto H; Ioi A; Mayumi A; Shimizu M; Sato M; Goto K; Inoue S; Yasui M; Inoue M
    Int J Hematol; 2022 Mar; 115(3):406-413. PubMed ID: 35028882
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Timing of Alemtuzumab With Respect to Day of Bone Marrow Infusion and its Effects Upon Engraftment and Graft-Versus-Host Disease in Patients With Sickle Cell Disease: A Single-Institutional Study.
    Sahdev I; Brochstein J; Werther N; Stiles J
    J Pediatr Hematol Oncol; 2020 Nov; 42(8):e718-e722. PubMed ID: 32890079
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.
    Ciurea SO; Saliba RM; Hamerschlak N; Karduss Aurueta AJ; Bassett R; Fernandez-Vina M; Petropoulos D; Worth LL; Chan KW; Couriel DR; Rondon G; Sharma M; Qazilbash M; Jones RB; Kebriaei P; McMannis J; Hosing CM; Nieto Y; Champlin RE; Shpall EJ; de Lima M
    Leuk Lymphoma; 2012 May; 53(5):901-6. PubMed ID: 21988645
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Posttransplant Cyclophosphamide for HLA-haploidentical Transplantation in Patients With Mucopolysaccharidosis.
    Yue Y; Song Z; Li J; Feng S; Liu R; Shi X
    J Pediatr Hematol Oncol; 2018 Aug; 40(6):e350-e354. PubMed ID: 29621063
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.
    Cutler C; Stevenson K; Kim HT; Brown J; McDonough S; Herrera M; Reynolds C; Liney D; Kao G; Ho V; Armand P; Koreth J; Alyea E; Dey BR; Attar E; Spitzer T; Boussiotis VA; Ritz J; Soiffer R; Antin JH; Ballen K
    Bone Marrow Transplant; 2011 May; 46(5):659-67. PubMed ID: 20697368
    [TBL] [Abstract][Full Text] [Related]  

  • 92. New Strategy of Acute Graft-vs-Host Disease: Investigation of a Reduced Dose of Antithymocyte Globulin in Haploidentical Hematopoietic Stem Cell Transplantation.
    Sun Y; Wei C; Cao C; Tan X; Zeng H; Luo Y; Chen L
    Transplant Proc; 2019 Apr; 51(3):890-895. PubMed ID: 30979481
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Reduced-intensity haploidentical peripheral blood stem cell transplantation using low-dose thymoglobulin for aggressive adult T cell leukemia/lymphoma patients in non-complete remission.
    Hirosawa M; Yamaguchi T; Tanaka A; Kominato Y; Higashi T; Morimoto H; Tsukada J
    Ann Hematol; 2020 Mar; 99(3):599-607. PubMed ID: 32006150
    [TBL] [Abstract][Full Text] [Related]  

  • 94. T-cell replete haploidentical stem cell transplantation with low dose anti-thymocyte globulin for relapsed/refractory Ewing sarcoma family tumors.
    Sano H; Mochizuki K; Kobayashi S; Ohara Y; Takahashi N; Kudo S; Ikeda K; Ohto H; Kikuta A
    Cancer Rep (Hoboken); 2022 Jul; 5(7):e1519. PubMed ID: 34291886
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Allogeneic stem cell transplantation after fludarabine, melphalan and thymoglobulin followed by early withdrawal of prophylactic immunosuppression in patients with acute lymphoblastic leukemia - update of single center study.
    Raida L; Kuba A; Rusinakova Z; Szotkowska R; Skoumalova I; Faber E; Szotkowski T; Rohon P; Hubacek J; Indrak K; Pikalova Z; Jarosova M; Divoka M; Langova K; Papajik T
    Neoplasma; 2017; 64(5):762-769. PubMed ID: 28592129
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Outcomes of Unrelated Donor Stem Cell Transplantion with Post-Transplant Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients with Severe Sickle Cell Disease.
    Rangarajan HG; Abu-Arja R; Pai V; Guilcher GMT; Soni S
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):413-417. PubMed ID: 29061531
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation.
    Salas MQ; Atenafu EG; Bautista MR; Prem S; Lam W; Datt Law A; Shaibani ZA; Kim DDH; Michelis FV; Lipton JH; Viswabandya A; Mattsson J; Kumar R
    Eur J Haematol; 2020 Jan; 104(1):36-45. PubMed ID: 31549435
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Successful Engraftment and Durable Graft-versus-host Disease Control with Haploidentical Peripheral Blood and a Short-term Conditioning Regimen for Primary Graft Failure.
    Tachibana T; Yamamoto E; Kawasaki R; Koharazawa H; Ishibashi D; Nakajima Y; Tanaka M; Matsumoto K; Ishigatsubo Y; Fujisawa S
    Intern Med; 2015; 54(21):2749-52. PubMed ID: 26521905
    [TBL] [Abstract][Full Text] [Related]  

  • 99. CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies.
    Holtan SG; Hogan WJ; Elliott MA; Ansell SM; Inwards DJ; Porrata LF; Johnston PB; Micallef IN; Lacy MQ; Gastineau DA; Litzow MR
    Bone Marrow Transplant; 2010 Dec; 45(12):1699-703. PubMed ID: 20208572
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts.
    Boulad F; Gillio A; Small TN; George D; Prasad V; Torok-Castanza J; Regan AD; Collins N; Auerbach AD; Kernan NA; O'Reilly RJ
    Br J Haematol; 2000 Dec; 111(4):1153-7. PubMed ID: 11167755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.